BridgeBio Pharma, Inc.
BBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $121 | $111 | $117 | $6 |
| % Growth | 9.2% | -5.2% | 1,882.9% | – |
| Cost of Goods Sold | $7 | $4 | $3 | $2 |
| Gross Profit | $114 | $107 | $114 | $4 |
| % Margin | 94.6% | 96.7% | 97.7% | 64.6% |
| R&D Expenses | $113 | $111 | $111 | $130 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $138 | $129 | $106 | $95 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $9 | $1 | $1 | $5 |
| Operating Expenses | $259 | $241 | $218 | $230 |
| Operating Income | -$145 | -$134 | -$104 | -$226 |
| % Margin | -120.3% | -121.4% | -89.5% | -3,842.7% |
| Other Income/Exp. Net | -$41 | -$47 | -$65 | -$40 |
| Pre-Tax Income | -$186 | -$182 | -$170 | -$266 |
| Tax Expense | -$2 | $2 | $0 | $1 |
| Net Income | -$183 | -$182 | -$167 | -$265 |
| % Margin | -151.4% | -164.5% | -143.5% | -4,506.1% |
| EPS | -0.96 | -0.95 | -0.88 | -1.4 |
| % Growth | -1.1% | -8% | 37.1% | – |
| EPS Diluted | -0.96 | -0.95 | -0.88 | -1.4 |
| Weighted Avg Shares Out | 191 | 191 | 190 | 189 |
| Weighted Avg Shares Out Dil | 191 | 191 | 190 | 189 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $4 | $5 | $5 |
| Interest Expense | $12 | $38 | $42 | $30 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$173 | -$143 | -$126 | -$235 |
| % Margin | -143.6% | -129.1% | -108.2% | -3,996.1% |